Stock 300636 JIANGXI SYNERGY PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jiangxi Synergy Pharmaceutical Co., Ltd.

Equities

300636

CNE100002P83

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
9.78 CNY +5.16% Intraday chart for Jiangxi Synergy Pharmaceutical Co., Ltd. -3.83% -7.21%
Jun. 24 Jiangxi Synergy Pharmaceutical Co., Ltd.(XSEC:300636) dropped from S&P Global BMI Index CI
May. 20 Jiangxi Synergy Pharmaceutical Co., Ltd. Approves Board Appointments CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The group's high margin levels account for strong profits.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • With a 2024 P/E ratio at 23.29 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. Stock Jiangxi Synergy Pharmaceutical Co., Ltd.
-7.21% 562M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
B+
NOVARTIS AG Stock Novartis AG
+13.83% 220B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
A+
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300636 Stock
  4. Ratings Jiangxi Synergy Pharmaceutical Co., Ltd.